Ventas Inc
For the period ended May 13, 2025. Filed Apr 1, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 13, 2025 · Filed Apr 1, 2025
Contents
Pay vs. Performance
2024 Pay vs. Performance
Pay vs. Performance Table
As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing the following information about “Compensation Actually Paid,” as defined by the SEC and in Note 2 below, and certain financial performance of the Company.
| Average SummaryCompensation Table Total for Other NEOs(1) · AverageCompensation Actually Paid to Other NEOs(2) · Value of Initial Fixed $100Investment Based On: · GAAPNetIncome(Loss)(in 000s) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Year · SummaryCompensationTable Total forCEO(1) · CompensationActually Paidto CEO(2) · TotalShareholderReturn(TSR) · FTSE NareitEquityHealth CareIndex TSR(3) · NormalizedFFO/Share(4) | ||||||||
| 2024 | $14,438,118 | $21,873,324 | $4,327,326 | $5,870,995 | $125.13 | $115.44 | $81,153 | $3.19 |
| 2023 | 13,520,625 | 10,139,836 | 4,107,540 | 3,806,036 | 102.39 | 92.96 | (40,973) | 2.99 |
| 2022 | 14,059,092 | 17,813,641 | 4,224,753 | 4,826,766 | 88.97 | 81.59 | (47,447) | 2.99 |
| 2021 | 14,263,728 | 9,914,452 | 6,012,810 | 5,967,437 | 97.29 | 104.85 | 49,008 | 2.90 |
| 2020 | 12,628,714 | 9,443,112 | 5,404,681 | 4,924,463 | 90.29 | 90.14 | 439,149 | 3.32 |
(1)The Named Executive Officers in the fiscal years identified above were:
| Year | CEO | Other NEOs |
| 2024 | Debra A. Cafaro | Robert F. Probst, Peter J. Bulgarelli, J. Justin Hutchens and Carey S. Roberts |
| 2023 | Debra A. Cafaro | Robert F. Probst, Peter J. Bulgarelli, J. Justin Hutchens and Carey S. Roberts |
| 2022 | Debra A. Cafaro | Robert F. Probst, Peter J. Bulgarelli, John D. Cobb and J. Justin Hutchens |
| 2021 | Debra A. Cafaro | Robert F. Probst, Peter J. Bulgarelli, John D. Cobb and J. Justin Hutchens |
| 2020 | Debra A. Cafaro | Robert F. Probst, John D. Cobb, J. Justin Hutchens and Carey S. Roberts |
(2)”Compensation Actually Paid”is defined by the SEC as the total compensation reported in the Summary Compensation Table for the applicable fiscal year adjusted as follows:
| Adjustments | CEO | Average Other NEOs |
|---|---|---|
| Deduction for Amounts Reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table for Applicable FY | (9,679,753) | (2,428,758) |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End | 11,466,516 | 2,873,864 |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date | — | — |
| Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End | 533,331 | 319,515 |
| Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date | 4,114,259 | 547,109 |
| Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End | (181,515) | (29,578) |
| Increase based on Dividends or Other Earnings Paid during Applicable FY prior to Vesting Date | 1,182,368 | 261,517 |
| Increase based on Incremental Fair Value of Options/SARs Modified during Applicable FY | — | — |
| Deduction for Change in the Actuarial Present Values reported under the “Change in Pension Value and Nonqualified Deferred Compensation Earnings” Column of the Summary Compensation Table for Applicable | — | — |
| Increase for Service Cost and, if applicable, Prior Service Cost for Pension Plans | — | — |
| TOTAL ADJUSTMENTS | 7,435,206 | 1,543,669 |
| 2025 | Proxy Statement | 83 |
|---|
(3)Total Shareholder Return and FTSE Nareit Equity Health Care Index Total Shareholder Return reflect the return a stockholder would have recognized at the end of each of the fiscal years shown had they invested $100 in the Company or the FTSE Nareit Equity Health Care Index, respectively, on January 1, 2020. We have chosen to include the FTSE Nareit Equity Health Care Index TSR as our peer group TSR in this table as this is one of the primary measures of performance used in our long-term incentive plan.
(4)Normalized FFO/Share is one of the primary measures used in our Annual Incentive Plan. Historical cost accounting for real estate assets implicitly assumes that the value of real estate assets diminishes predictably over time. However, because real estate values historically have risen or fallen with market conditions, many industry investors deem presentations of operating results for real estate companies that use historical cost accounting to be insufficient by themselves. For that reason, we consider Funds From Operations attributable to common stockholders (“FFO”) and Normalized FFO to be appropriate supplemental measures of operating performance of an equity REIT. For information regarding the calculation of Normalized FFO, please see page 55 of our Form 10-K for the year ended December 31, 2024. To calculate Normalized FFO on per share basis, Normalized FFO is divided by weighted average diluted shares.
| 84 | 2025 | Proxy Statement |
Relationship Between Compensation Actually Paid and Financial Performance Measures
The line graphs below compare Compensation Actually Paid to our CEO and the average Compensation Actually Paid to our Other NEOs to (i) our cumulative TSR, (ii) FTSE Nareit Equity Health Care Index TSR (“Nareit TSR”), (iii) our Net Income (Loss) and (iv) our Normalized FFO/Share, in each case, for the fiscal years ended December 31, 2020, 2021, 2022, 2023 and 2024.
TSR amounts assume an initial fixed investment of $100, and that any dividends were reinvested.
Compensation Actually Paid Versus Cumulative TSR
| CEO Compensation Actually Paid ($) | Other NEO Average Compensation Actually Paid ($) |
| Ventas Total Shareholder Return ($) | FTSE NAREIT Equity Health Care Index TSR ($) |
Compensation Actually Paid Versus Net Income (Loss) (in $000s)
| CEO Compensation Actually Paid ($) | Other NEO Average Compensation Actually Paid ($) |
| Net Income (in $000s) |
| 2025 | Proxy Statement | 85 |
|---|
Compensation Actually Paid Versus Normalized Funds from Operations per Share ($)
| CEO Compensation Actually Paid ($) | Other NEO Average Compensation Actually Paid ($) |
| Normalized Funds from Operations per Share ($) |
Key Financial Performance Measures
The following performance measures represent the most important financial performance measures used by us to link compensation actually paid to our Named Executive Officers for the fiscal year ended December 31, 2024 to company performance:
Financial Performance Measures Linked to the Compensation of Named Executive Officers
Normalized FFO per Share
Fixed Charge Coverage
TSR Relative to the FTSE Nareit Equity Health Care Index
TSR Relative to the MSCI U.S. REIT Index
Net Debt to Further Adjusted EBITDA
See the discussions of our annual and long-term incentive programs in “Compensation Discussion & Analysis” for further information regarding the use of these measures in our executive compensation program.
| 86 | 2025 | Proxy Statement |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.